CytoMed Therapeutics Ltd., a company based in Singapore and trading under the symbol GDTC, announced on Monday a strategic alliance with SunAct Cancer Institute Private Limited, located in India. This Business & Research Collaboration Agreement (BRCA) is set for a duration of five years.
This collaboration aims to explore and assess the safety, tolerability, potency, and efficacy of CytoMed's proprietary allogeneic gamma delta T cells. These cells are intended for the treatment of various cancers, including solid tumors, through clinical research. The collaboration will encompass a Phase 2 investigator-initiated trial in India.
Both CytoMed and SunAct, headquartered in Mumbai, will serve as joint sponsors for the clinical trial, collaborating closely with the medical team at the SunAct Cancer Institute. The trial will be spearheaded by Dr. Vijay Patil, a medical oncologist, immunotherapy specialist, and founder of SunAct.
CytoMed has committed to providing scientific and technical support for the trial's planning and execution while also being responsible for producing the investigational product, the allogeneic gamma delta T cells.
Dr. Patil expressed expectations to identify the cancer types responsive to this therapy, as well as any potential side effects and their mitigation strategies.
Peter Choo, Chairman of CytoMed, stated, "Our partnership with SunAct aligns perfectly with our mission to leverage CytoMed's proprietary off-the-shelf technologies in developing innovative, donor-derived cell-based allogeneic immunotherapies for various cancers at a cost-effective price. We share SunAct's vision of offering affordable cancer treatments to improve patients' quality of life."
